4-Chlorophenyl Isocyanate | CAS:104-12-1

We serve 4-Chlorophenyl Isocyanate CAS:104-12-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Chlorophenyl Isocyanate

Chemical Name:4-Chlorophenyl Isocyanate
CAS.NO:104-12-1
Synonyms:4-Chlorophenyl Isocyanate
Isocyanic Acid 4-Chlorophenyl Ester
p-Chlorophenyl isocyanate
1-Chloro-4-isocyanatobenzene
 
Physical and Chemical Properties:
Density 1.2±0.1 g/cm3
Boiling Point 204.2±13.0 °C at 760 mmHg
Melting Point 26-29 °C(lit.)
Molecular Formula C7H4ClNO
Molecular Weight 153.566
Flash Point 76.0±9.1 °C
Vapour Pressure 0.3±0.4 mmHg at 25°C
Index of Refraction 1.551
 
Specification:
Appearance:White crystal
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Diflubenzuron(CAS:35367-38-5).



Contact us for information like 4-Chlorophenyl Isocyanate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Chloro-4-isocyanatobenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Chlorophenyl Isocyanate Use and application,p-Chlorophenyl isocyanate technical grade,usp/ep/jp grade.


Related News: On the other hand, the company has many new products in recent years, including Duqiao Base, Yancheng United Chemical and Dezhou United Chemical. These new products are mostly customized products with strong profitability, which has improved the gross profit margin of the industrial business.2,5-Dibromopyridine manufacturer Professionally produce and submit DMF files, and supplement data at any time during the patent challenge of formulation companies.Methyl 3-chlorosulfonylthiophene-2-carboxylate supplier The use of contrast agents is different from other drugs, and it needs to be used with corresponding equipment. In recent years, China is in the growth period of imaging equipment.cyclohexanecarbaldehyde vendor The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.At present, Teva can produce more than 300 generic drugs, and the API department has approximately 650 authorized patents and patent applications worldwide. It is also the generic drug company with the most challenges in patenting ParagraphIV in the world.